Mylan's Nationwide Recall of Valsartan Tablets Expanded

Published Online: Tuesday, December 4th, 2018
Officials with Mylan Pharmaceuticals today announced that they are expanding a consumer-level voluntary nationwide recall to include all lots of valsartan-containing products within expiry.

The 104 additional lots include 26 lots of amlodipine and valsartan tablets, USP (including the 5 mg/160 mg, 10 mg/160 mg, 5 mg/320  mg and 10 mg/320 mg strengths), 51 lots of valsartan tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of valsartan and hydrochlorothiazide tablets, USP (80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg strengths).  

According to a statement from Mylan, these products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API valsartan, USP, manufactured by Mylan Laboratories Limited. NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen according to the International Agency for Research on Cancer (IARC).

The finished products are manufactured by Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited. These batches were distributed in the United States between March 2017 and November 2018. 

The expanded recalled batches can be found here

This article was originally published on PharmacyTimes.com 





Current Issue

The Educated Patient

Kristen Marjama, DNP, APRN-BC
Although the rate of foot and leg amputation has greatly declined over the past 2 decades, increasing awareness for macrovascular and microvascular complications of diabetes is essential because diabetes is the leading cause of lower-limb amputations in the United States.
Kristen Marjama, DNP, FNP-BC
Gluten proteins found in barley, rye, and wheat trigger systemic injury primarily to the small intestine, but they can also affect the joints, liver, skin, uterus, and other organs.
Kristen Marjama, DNP, FNP-BC
It is that time of year again, when health care providers see an increase in patient volume because no one has time to be sick.
Sara Marlow, MSN, RN, PHN, FNP-C
Sunburn is still a major health issue that can be prevented.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
ONCLive
OTCGuide
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Advertise
Careers
Contact Us
Feedback
Privacy
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2018
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.